NCT06343714

A Study of FB1003 in Healthy Subject

Name: Clinical Trial NCT06343714
Creator: 4B Technologies Limited
Keywords: Healthy Volunteers, FB1003, Phase 1, drug, clinical trial

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Escalating Single and Multiple Doses of FB1003 in the Healthy Subjects

4B Technologies Limited·Phase 1·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Healthy Volunteers
Drug/Device/Intervention: FB1003
Study type: Interventional
Intervention type: drug

Sponsor & location

Primary sponsor: 4B Technologies Limited

Timeline & enrollment

Phase: Phase 1
Start date: Apr 03, 2024
End date: Jun 30, 2025
Enrollment: 64 participants

Primary outcome

The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with FB1003 or placebo.

Summary

The purpose of this study is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants. Blood tests will be done to examine blood exposure, concentration and half-life of FB1003 following administrations. For each participant, the study will last up to about 12 weeks for single ascending dose part, and 18 weeks for multiple ascending dose part, including screening.

ICD-10 classifications

Healthy person accompanying sick personRoutine general health check-up of armed forcesRoutine general health check-up of sports teamsRoutine general health check-up of inhabitants of institutions

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06343714
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06343714 through Pure Global AI's free database. This Phase 1 trial is sponsored by 4B Technologies Limited and is currently Not yet recruiting. The study focuses on Healthy Volunteers. Target enrollment is 64 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.